Logical Assessment
Latest Articles
Otonomy's $525 Million Dive Is Fennec's Good Fortune
Jazz Pharma To Play Its Acquisition Riffs Again: All Notes Point To 2 Otology Companies
How To Capitalize On Trump's America, Coal (And Algae) Is The New Solar
Mama Never Told Me About These Meatballs
VistaGen Is An Interesting Opportunity, Following Allergan's Anti-Depressant Investment In Naurex
A Well Of Catalysts Foreshadows Meaningful Appreciation For eWellness
Decision Diagnostics: Meaningfully Derisked And Substantially Undervalued
Opportunity Within The Multi-Billion Physical Therapy Industry: Examining U.S. Physical Therapy And EWellness
A Celgene Satellite: An Interview With Alliqua CEO Dave Johnson
Cardax Pharma: Addressing The Growing Inflammation Market With Nature's Answer
Cynapsus Represents A Compelling Acquisition Target For Acadia Pharmaceuticals
San Fran Biotech Week Aftermath: Advaxis Is Primed To Take Off
While Amarin Continues To Go Rancid, Neptune Will Soar
The Immunotherapy Company You Never Saw Coming: Advaxis CSO Interview
GlassesOff: The Most Disruptive Technology In Mobile
Advaxis' S-1 Filing Foreshadows Imminent Uplisting To NASDAQ
Organovo May Be Big Pharma's Salvation
6 Reasons Advaxis May Be The Best Reward Vs. Risk In Healthcare
An Incredibly Asymmetric Risk/Reward Ratio For Sanuwave Foreshadows Huge Upside
Has Illumina Set Its Sights On TrovaGene As Its Next Acquisition?
As The Patent Cliff Approaches, Buy TrovaGene
Sunshine Heart Quietly Reports Breakthrough In Congestive Heart Failure Treatment
The 4 Healthcare Companies Investors Should Be Watching
Why Royalty And Milestone Partnership Dynamics Imply Trovagene Could Triple
Analyzing Market Efficiency: Why Future Catalysts Imply Sanuwave Still Has Room To Double
ARM Holdings' Biotech Twin: FluoroPharma
Biotech's Fallen Angels: Identifying Irrational Market Behavior
The Shockwave Device That Heals: The SanuWave Opportunity
Positive Top Line Data For Synergy: A Ripe Time For Acquisition
Takeaways From Teva's Analyst Day: 'Restoring Shareholder Value'
Is Sunshine The Solution To Device Tax Blues?
Synergy CEO Reveals Why Investors Are Eagerly Anticipating Key Data